ArriVent BioPharma Reports Promising Results From Phase 1b Trial for Firmonertinib in NSCLC

ArriVent BioPharma Reports Promising Results from Phase 1b Trial for Firmonertinib in NSCLC

NEWTOWN SQUARE, PA — ArriVent BioPharma, Inc. (Nasdaq: AVBP) has shared encouraging interim results from its Phase 1b FURTHER trial, which investigates firmonertinib as a first-line monotherapy for non-small cell lung cancer (NSCLC) patients with EGFR PACC mutations. The findings highlight firmonertinib’s potential to address a critical gap in the treatment of this underserved population. The study reported a median progression-free survival (mP…

ArriVent reports encouraging data from firmonertinib monotherapy study in NSCLC - BioTuesdays

ArriVent BioPharma (NASDAQ: AVBP) announced encouraging additional follow-up proof-of-concept data from its global Phase 1b FURTHER trial of first-line firmonertinib monotherapy in patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) P-loop alpha-C helix-compressing (PACC) mutations. The company also provided a clinical development update on the firmonertinib program for the treatment of ECFR PACC-mu…